Generate Biomedicines, Inc. (GENB) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.80B USD. 52-week range 11.00 to 22.67 USD. Data as of 2026-10-09.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; ...